Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
361.96 USD | -5.14% | +0.08% | -26.71% |
01:15pm | Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree... | |
11:44am | B. Riley Initiates Ulta Beauty at Sell With $300 Price Target | MT |
Fiscal Period: February | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 13.98 | 3.75 | 16.41 | 20.21 | 18.94 | |||||
Return on Total Capital | 19.9 | 4.83 | 22.21 | 28.27 | 26.05 | |||||
Return On Equity % | 37.93 | 9.01 | 55.78 | 71.09 | 60.91 | |||||
Return on Common Equity | 37.93 | 9.01 | 55.78 | 71.09 | 60.91 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 40.54 | 37.95 | 43.54 | 43.59 | 42.95 | |||||
SG&A Margin | 28.1 | 32.85 | 28.44 | 27.44 | 27.91 | |||||
EBITDA Margin % | 16.16 | 9.68 | 18.09 | 18.41 | 17.14 | |||||
EBITA Margin % | 12.18 | 4.86 | 14.99 | 16.05 | 14.97 | |||||
EBIT Margin % | 12.18 | 4.86 | 14.99 | 16.05 | 14.97 | |||||
Income From Continuing Operations Margin % | 9.54 | 2.86 | 11.42 | 12.17 | 11.52 | |||||
Net Income Margin % | 9.54 | 2.86 | 11.42 | 12.17 | 11.52 | |||||
Net Avail. For Common Margin % | 9.54 | 2.86 | 11.42 | 12.17 | 11.52 | |||||
Normalized Net Income Margin | 7.66 | 2.98 | 9.35 | 10.06 | 9.46 | |||||
Levered Free Cash Flow Margin | 8.28 | 10.3 | 8.85 | 9.69 | 6.99 | |||||
Unlevered Free Cash Flow Margin | 8.28 | 10.36 | 8.86 | 9.69 | 6.99 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.84 | 1.24 | 1.75 | 2.01 | 2.02 | |||||
Fixed Assets Turnover | 3.73 | 2.35 | 3.52 | 4.11 | 4.21 | |||||
Receivables Turnover (Average Receivables) | 53.71 | 37.01 | 40.45 | 47.14 | 55.02 | |||||
Inventory Turnover (Average Inventory) | 3.51 | 3.1 | 3.65 | 3.62 | 3.73 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.81 | 1.87 | 1.46 | 1.61 | 1.71 | |||||
Quick Ratio | 0.56 | 0.92 | 0.43 | 0.56 | 0.59 | |||||
Operating Cash Flow to Current Liabilities | 0.97 | 0.6 | 0.68 | 0.88 | 0.89 | |||||
Days Sales Outstanding (Average Receivables) | 6.78 | 9.83 | 9 | 7.72 | 6.74 | |||||
Days Outstanding Inventory (Average Inventory) | 103.77 | 117.37 | 99.62 | 100.64 | 99.34 | |||||
Average Days Payable Outstanding | 33.24 | 43.93 | 36.01 | 34.53 | 31.35 | |||||
Cash Conversion Cycle (Average Days) | 77.3 | 83.28 | 72.61 | 73.83 | 74.73 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 101.91 | 94.86 | 120.28 | 97.11 | 83.84 | |||||
Total Debt / Total Capital | 50.47 | 48.68 | 54.6 | 49.27 | 45.61 | |||||
LT Debt/Equity | 89.31 | 82.19 | 102.43 | 82.66 | 71.39 | |||||
Long-Term Debt / Total Capital | 44.23 | 42.18 | 46.5 | 41.93 | 38.83 | |||||
Total Liabilities / Total Assets | 60.89 | 60.72 | 67.77 | 63.51 | 60.06 | |||||
EBIT / Interest Expense | - | 52.09 | 777.79 | - | - | |||||
EBITDA / Interest Expense | - | 170.99 | 1.17K | - | - | |||||
(EBITDA - Capex) / Interest Expense | - | 144.51 | 1.07K | - | - | |||||
Total Debt / EBITDA | 1.28 | 1.93 | 0.95 | 0.83 | 0.81 | |||||
Net Debt / EBITDA | 0.95 | 0.87 | 0.73 | 0.51 | 0.49 | |||||
Total Debt / (EBITDA - Capex) | 1.6 | 2.29 | 1.04 | 0.97 | 1 | |||||
Net Debt / (EBITDA - Capex) | 1.18 | 1.03 | 0.8 | 0.59 | 0.6 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 10.15 | -16.84 | 40.3 | 18.28 | 9.78 | |||||
Gross Profit, 1 Yr. Growth % | 24.48 | -23.39 | 60.96 | 18.43 | 8.18 | |||||
EBITDA, 1 Yr. Growth % | 5.52 | -50.19 | 162.1 | 20.37 | 2.24 | |||||